In Q1 2026, Intensity Therapeutics recorded a net loss of $2.4 million, compared with a $3.3 million loss in Q1 2025. Research and development expenses fell to $1.2 million from $2.2 million, driven by reduced INVINCIBLE-3 Study costs, while general and administrative expenses increased to $1.3 million due to bonus accruals. Cash and cash equivalents stood at $10.2 million as of March 31, 2026.

The Phase 2 INVINCIBLE-4 Study in early-stage operable triple negative breast cancer showed that 5 of 7 patients (71.4%) who received INT230-6 before standard of care achieved pathological complete response versus 33% in the SOC arm, with grade 3 or higher adverse events reduced by 44%. Swissmedic granted approval on March 26, 2026, to resume enrollment, which the company plans to restart in Q2 2026 and extend to France later in the year. Detailed cohort results are expected at an upcoming oncology conference.

Enrollment in the Phase 3 INVINCIBLE-3 Study, paused in March 2025 due to funding constraints, will resume at select U.S. sites in Q3 2026, with full site activation contingent on additional capital. In March 2026, the company established a $60 million ATM facility to support judicious cash burn management and ongoing pharmacovigilance activities for the 21 patients already enrolled.